Past success is an excellent of predictor of future success in commercialization. Our achievements demonstrate that BLG has the skills, knowledge and experience to help you.

Read highlights below for a selection of featured license agreements and licensing relationships with established industry partners, investor groups, and startup companies, as well as collaboration with our peer academic institutions to commercialize jointly-developed inventions.

Developments with Longstanding Licensing Relationships

Takeda Pharmaceuticals

A Decade of Academia-Industry Joint Efforts in Developing a Human Norovirus Vaccine Candidate.

Opexa Therapeutics, Inc.

Opexa Therapeutics Reaches Clinical Development Milestone Event in Development of a Personalized Therapy for Secondary Progressive Multiple Sclerosis.

TyRx, Inc.

TyRx, Inc., Expands Market and Introduces Bioresorbable AIGISRx R Antibacterial Envelope.

Exclusive License Agreements

Celgene Corporation

Celgene, bluebird bio, and the Center for Cell and Gene Therapy Combine Strengths and Resources to Develop T-cell Based Therapies for Cancer

Vax-Immune, LLC

Vax-Immune Acquires Exclusive Worldwide Rights to Baylor College of Medicine’s Ureaplasma Technology.

Shenzhen Tiande Investment Co., LTD.

Shenzhen Tiande Investment Co., LTD., Licenses Esophageal Cancer Biomarkers.

Acer Therapeutics, Inc.

Acer Therapeutics Develops the First Pharmaceutical Therapy for Maple Syrup Urine Disease (MSUD)

StemMed, Ltd.

StemMed, Ltd., Licenses STAT3 Inhibitors - Local Company Developing Novel Compounds Against a Key Cancer Target

Non-Exclusive Licensed Technologies

pINDUCER Lentiviral Vectors

pINDUCER Lentiviral Vectors for Inducible RNAi in vitro and in vivo.

The TRAMP Mouse Model and Cell Lines

The TRAMP Mouse Model and Cell Lines - A Research Tool’s Popularity Marches On

Master Agreements

American Type Culture Collection (ATCC)

ATCC Master Agreement - BCM Poised to Benefit from Commercial Use of Deposited Materials.